Indi Molecular

Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics. PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic. For radiotherapy this dual role is accomplished by choice of the complexed radionuclide sharing the same chelation chemistry. Chemotherapy can similarly be specifically delivered to diseased cells by the protein catalyzed capture technology. The company launched in 2013 with a $1.8 million seed round, followed by an $11.5 million Series A in 2017.